Application of LIVERFASt biomarkers to evaluate longitudinal hepatic fibrosis and inflammation after HCV cure easlfibronostg on June 26, 2026 Category: Publications Tag: Hep B, Hep C, LIVERFASt, Monitoring Post navigation Previous: Previous post: Application of LIVERFASt to predict steatosis in Chronic Hepatitis B patients with metabolic syndromeNext: Next post: Comparative Assessment of NIMs (LIVERFASt/ELF/FIB-4/LSM) in a prospective cohort with chronic liver diseases (Thailand)
